Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Enterprise Value (2019 - 2025)

Lyell Immunopharma's Enterprise Value history spans 7 years, with the latest figure at -$196.0 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 55.5% year-over-year to -$196.0 million; the TTM value through Jun 2025 reached -$276.8 million, up 43.64%, while the annual FY2024 figure was -$370.5 million, 32.17% up from the prior year.
  • Enterprise Value for Q3 2025 was -$196.0 million at Lyell Immunopharma, up from -$276.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$180.8 million in Q1 2025 and bottomed at -$824.5 million in Q2 2021.
  • The 5-year median for Enterprise Value is -$546.2 million (2023), against an average of -$485.4 million.
  • The largest annual shift saw Enterprise Value plummeted 358.87% in 2021 before it skyrocketed 75.05% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$614.8 million in 2021, then dropped by 4.12% to -$640.2 million in 2022, then rose by 14.67% to -$546.2 million in 2023, then surged by 32.17% to -$370.5 million in 2024, then surged by 47.09% to -$196.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Enterprise Value are -$196.0 million (Q3 2025), -$276.8 million (Q2 2025), and -$180.8 million (Q1 2025).